Short answer
When developing and launching new high-value therapeutic products, anticipate that pricing will be influenced by existing market benchmarks and potentially by complex discount structures, rather than solely by the incremental benefit provided.
- Field
- Innovation & Markets
- Source
- The Journal of Economic Perspectives (2015)
- Method
- Quantitative analysis of historical drug pricing data.
- Sample
- 58 anticancer drugs
- Evidence
- Strong effect
The launch prices of new anticancer drugs have seen a consistent annual increase of 10%, driven by market structures that allow manufacturers to price new therapies relative to existing ones. This innovation & markets research insight is drawn from a 2015 study published in The Journal of Economic Perspectives. Using Quantitative analysis of historical drug pricing data. with 58 anticancer drugs, researchers explored how this design variable affects real-world outcomes. The key design takeaway: When developing and launching new high-value therapeutic products, anticipate that pricing will be influenced by existing market benchmarks and potentially by complex discount structures, rather than solely by the incremental benefit provided.
Anticancer Drug Launch Prices Rise 10% Annually Due to Market Dynamics
The launch prices of new anticancer drugs have seen a consistent annual increase of 10%, driven by market structures that allow manufacturers to price new therapies relative to existing ones.
The Journal of Economic Perspectives · 2015
Key Findings
- 01The average launch price of anticancer drugs, adjusted for inflation and health benefits, increased by 10% annually from 1995 to 2013.
- 02Institutional features of the anticancer drug market enable manufacturers to set prices based on existing therapies.
- 03Government-mandated price discounts for certain buyer classes may contribute to higher overall launch prices.
Application
Design takeaway
When developing and launching new high-value therapeutic products, anticipate that pricing will be influenced by existing market benchmarks and potentially by complex discount structures, rather than solely by the incremental benefit provided.
How to apply
When forecasting revenue or assessing the economic viability of a new drug, incorporate an understanding of how competitor pricing and market access policies will influence the achievable launch price.
Project actions
- 01When researching a new product category, investigate the existing pricing structures and how new entrants typically position themselves.
- 02Consider how market regulations or common business practices might influence the pricing of your proposed design.
Method & Evidence
Variables
Strengths & Limitations
Strengths
- +Longitudinal data analysis over a significant period.
- +Inclusion of health benefits in price adjustment provides a more nuanced view than raw price increases.
Limitations
The pricing of drugs is complex and influenced by many factors not fully captured in this study, such as R&D investment, manufacturing costs, and perceived value by patients and payers.
Reliability & validity
The study's reliability is supported by its quantitative approach and focus on a specific drug class. Validity is enhanced by adjusting prices for inflation and health benefits, though the measurement of 'health benefits' could be a point of discussion.
Think critically
To what extent should the 'value' of an innovation be determined by market forces versus its objective impact on users or society?
Design Principles
"Market-driven pricing strategies can lead to escalating costs for innovative products, independent of their direct impact on user outcomes."
This trend highlights how market dynamics, rather than solely therapeutic benefit, can dictate pricing strategies for innovative products. Understanding these mechanisms is crucial for stakeholders involved in product development, market access, and healthcare policy.
What This Means for Your Design
New cancer drugs are getting more expensive each year because companies tend to price them based on what other similar drugs cost, not just how much better they are. This means prices go up steadily, even when you factor in the extra life years they give patients.
How to use in your project
- 1.Use this research to justify the pricing strategy for a new product, explaining how it aligns with or deviates from established market trends.
- 2.Reference this study when discussing the economic factors influencing the adoption and diffusion of innovative products.
Add to My Project
Quick Cite
Paragraph starter
The pricing of innovative products, particularly in specialized markets like pharmaceuticals, is significantly shaped by market dynamics. Research indicates that in the anticancer drug market, launch prices have seen a consistent annual increase of 10%, driven by institutional features that allow manufacturers to price new therapies relative to existing ones. This suggests that a product's price is not solely determined by its functional benefits but also by its positioning within a competitive landscape and the broader economic structure of its market.
Source
The Journal of Economic Perspectives
Pricing in the Market for Anticancer Drugs
journal · 2015
View sourceQuestions About This Research
- What does the research say about anticancer drug launch prices rise 10% annually due to market dynamics?
- When developing and launching new high-value therapeutic products, anticipate that pricing will be influenced by existing market benchmarks and potentially by complex discount structures, rather than solely by the incremental benefit provided. Evidence: The Journal of Economic Perspectives (2015).
- Why does "Anticancer Drug Launch Prices Rise 10% Annually Due to Market Dynamics" matter for design?
- This trend highlights how market dynamics, rather than solely therapeutic benefit, can dictate pricing strategies for innovative products. Understanding these mechanisms is crucial for stakeholders involved in product development, market access, and healthcare policy.
- How can designers apply this research?
- When developing and launching new high-value therapeutic products, anticipate that pricing will be influenced by existing market benchmarks and potentially by complex discount structures, rather than solely by the incremental benefit provided.
- What were the main findings?
- The average launch price of anticancer drugs, adjusted for inflation and health benefits, increased by 10% annually from 1995 to 2013.. Institutional features of the anticancer drug market enable manufacturers to set prices based on existing therapies.. Government-mandated price discounts for certain buyer classes may contribute to higher overall launch prices.
- What research method was used?
- Quantitative analysis of historical drug pricing data. with 58 anticancer drugs.
- How strong is the evidence?
- Evidence strength is rated Strong effect, based on a 2015 journal from The Journal of Economic Perspectives.
- What should I do differently in my next project?
- When forecasting revenue or assessing the economic viability of a new drug, incorporate an understanding of how competitor pricing and market access policies will influence the achievable launch price.
- What are the limitations?
- The study focuses specifically on anticancer drugs, and the findings may not be generalizable to all pharmaceutical markets. The analysis of 'health benefits' is based on median survival time, which may not capture all aspects of patient well-being.